Avidity Biosciences (RNA) News Today $32.38 -0.16 (-0.48%) As of 11:40 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Avidity Biosciences, Inc. (NASDAQ:RNA) Given Average Rating of "Buy" by AnalystsAvidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) has earned a consensus recommendation of "Buy" from the ten research firms that are currently covering the firm, Marketbeat reports. Ten analysts have rated the stock with a buy rating. The average 1-year price objective among analysts thatFebruary 21 at 4:04 AM | marketbeat.comAvidity Biosciences (RNA) to Release Quarterly Earnings on WednesdayAvidity Biosciences (NASDAQ:RNA) will be releasing earnings before the market opens on Wednesday, February 26.February 19 at 3:07 AM | marketbeat.comLegato Capital Management LLC Invests $301,000 in Avidity Biosciences, Inc. (NASDAQ:RNA)Legato Capital Management LLC acquired a new stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 10,337 shares of the biotechnology company's stocFebruary 15, 2025 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Stock Price Down 7% - Here's What HappenedAvidity Biosciences (NASDAQ:RNA) Trading Down 7% - Here's WhyFebruary 12, 2025 | marketbeat.comabrdn plc Buys 20,076 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)abrdn plc raised its stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 80.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 44,912 shares of the biotechnology company's stock after purchasing an additiFebruary 11, 2025 | marketbeat.comKathleen P. Gallagher Sells 5,875 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) StockFebruary 6, 2025 | insidertrades.comAvidity Biosciences chief program officer sells $188,918 in stockFebruary 5, 2025 | msn.comInsider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells 5,875 Shares of StockAvidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) insider Kathleen P. Gallagher sold 5,875 shares of the company's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $32.16, for a total value of $188,940.00. Following the transaction, the insider now owns 50,554 shares of the company's stock, valued at approximately $1,625,816.64. This represents a 10.41 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.February 5, 2025 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Trading Up 6% - Time to Buy?Avidity Biosciences (NASDAQ:RNA) Trading Up 6% - What's Next?January 27, 2025 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) Given Consensus Rating of "Buy" by BrokeragesAvidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) has been assigned an average recommendation of "Buy" from the ten ratings firms that are currently covering the company, Marketbeat reports. Ten investment analysts have rated the stock with a buy rating. The average twelve-month target pricJanuary 27, 2025 | marketbeat.comAssenagon Asset Management S.A. Purchases New Position in Avidity Biosciences, Inc. (NASDAQ:RNA)Assenagon Asset Management S.A. acquired a new stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 40,559 shares of the biotechnology cJanuary 25, 2025 | marketbeat.comAvidity Biosciences chief program officer sells shares worth $206,799January 24, 2025 | msn.comAvidity Biosciences CFO sells $93,985 in stockJanuary 24, 2025 | msn.comAvidity Biosciences, Inc. (NASDAQ:RNA) Director Sells $53,539.20 in StockJanuary 24, 2025 | insidertrades.comArthur A. Levin Sells 1,872 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) StockAvidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) Director Arthur A. Levin sold 1,872 shares of the company's stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $28.60, for a total transaction of $53,539.20. Following the sale, the director now owns 12,958 shares in the company, valued at $370,598.80. The trade was a 12.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.January 23, 2025 | marketbeat.comInsider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells 2,959 Shares of StockAvidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) insider Teresa Mccarthy sold 2,959 shares of the stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $28.59, for a total transaction of $84,597.81. Following the transaction, the insider now directly owns 104,908 shares in the company, valued at $2,999,319.72. This trade represents a 2.74 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.January 23, 2025 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) CFO Michael F. Maclean Sells 3,287 SharesAvidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) CFO Michael F. Maclean sold 3,287 shares of the firm's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $28.59, for a total value of $93,975.33. Following the completion of the sale, the chief financial officer now owns 104,655 shares in the company, valued at $2,992,086.45. The trade was a 3.05 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.January 23, 2025 | marketbeat.comSarah Boyce Sells 10,397 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) StockAvidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) CEO Sarah Boyce sold 10,397 shares of the firm's stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $28.59, for a total value of $297,250.23. Following the completion of the transaction, the chief executive officer now owns 337,411 shares of the company's stock, valued at approximately $9,646,580.49. The trade was a 2.99 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.January 23, 2025 | marketbeat.comAvidity Biosciences (RNA) Gets a Buy from RBC CapitalJanuary 22, 2025 | markets.businessinsider.comFY2025 Earnings Estimate for RNA Issued By Cantor FitzgeraldAvidity Biosciences, Inc. (NASDAQ:RNA - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Avidity Biosciences in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt expects that theJanuary 22, 2025 | marketbeat.comEquities Analysts Set Expectations for RNA Q1 EarningsAvidity Biosciences, Inc. (NASDAQ:RNA - Free Report) - Stock analysts at Leerink Partnrs reduced their Q1 2025 earnings per share (EPS) estimates for shares of Avidity Biosciences in a research report issued on Monday, January 20th. Leerink Partnrs analyst J. Schwartz now forecasts that the bioteJanuary 22, 2025 | marketbeat.comRoyal Bank of Canada Reiterates Outperform Rating for Avidity Biosciences (NASDAQ:RNA)Royal Bank of Canada reaffirmed an "outperform" rating and set a $67.00 price target on shares of Avidity Biosciences in a research report on Tuesday.January 21, 2025 | marketbeat.comAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 20, 2025 | prnewswire.comAvidity Biosciences, Inc. (RNA): The Biotech Stock with Biggest Upside PotentialJanuary 17, 2025 | insidermonkey.comBank of America Securities Remains a Buy on Avidity Biosciences (RNA)January 16, 2025 | markets.businessinsider.comAvidity Biosciences: Strategic Advancements in Key Programs Drive Buy RatingJanuary 15, 2025 | markets.businessinsider.comBarclays Keeps Their Buy Rating on Avidity Biosciences (RNA)January 13, 2025 | markets.businessinsider.comAvidity Biosciences (NASDAQ:RNA) Sees Large Volume Increase - Here's WhyAvidity Biosciences (NASDAQ:RNA) Sees Strong Trading Volume - What's Next?January 10, 2025 | marketbeat.comAvidity Biosciences' (RNA) Buy Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $72.00 price target on shares of Avidity Biosciences in a report on Friday.January 10, 2025 | marketbeat.comAvidity Biosciences plans BLA submission for delpacibart zotadirsenJanuary 9, 2025 | markets.businessinsider.comAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 8, 2025 | prnewswire.comAvidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025January 8, 2025 | prnewswire.comAvidity Biosciences, Inc. (NASDAQ:RNA) Given Consensus Recommendation of "Buy" by AnalystsShares of Avidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) have been given a consensus rating of "Buy" by the eleven analysts that are covering the stock, MarketBeat Ratings reports. Eleven analysts have rated the stock with a buy rating. The average 1-year price objective among brokers thJanuary 2, 2025 | marketbeat.comWhy Is Avidity Biosciences, Inc. (RNA) Among the Best Multibagger Stocks to Buy Right Now?January 1, 2025 | msn.comAvidity Biosciences (NASDAQ:RNA) Trading Down 5.4% - Here's WhyAvidity Biosciences (NASDAQ:RNA) Trading Down 5.4% - Should You Sell?December 30, 2024 | marketbeat.comAvidity Biosciences Inc Ordinary SharesDecember 28, 2024 | morningstar.comFranklin Resources Inc. Buys 50,908 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)Franklin Resources Inc. increased its stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 229.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 73,047 shares of the biotechnology company's stock after buyingDecember 25, 2024 | marketbeat.comWhat is Chardan Capital's Estimate for RNA FY2024 Earnings?Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) - Equities researchers at Chardan Capital reduced their FY2024 earnings per share estimates for shares of Avidity Biosciences in a note issued to investors on Wednesday, December 18th. Chardan Capital analyst K. Nakae now anticipates that the bDecember 23, 2024 | marketbeat.comPromising Advancements and Strategic Growth: A Buy Rating for Avidity BiosciencesDecember 22, 2024 | markets.businessinsider.comAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 20, 2024 | prnewswire.comHC Wainwright & Co. Initiates Coverage of Avidity Biosciences (RNA) with Buy RecommendationDecember 20, 2024 | msn.comAvidity Biosciences (NASDAQ:RNA) Shares Up 3.2% - Time to Buy?Avidity Biosciences (NASDAQ:RNA) Stock Price Up 3.2% - Time to Buy?December 20, 2024 | marketbeat.comAvidity Biosciences initiated with a Buy at H.C. WainwrightDecember 20, 2024 | markets.businessinsider.comWhat 8 Analyst Ratings Have To Say About Avidity BiosciencesDecember 20, 2024 | benzinga.comInsider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) CFO Sells 11,151 Shares of StockDecember 20, 2024 | insidertrades.comAvidity Biosciences (NASDAQ:RNA) Coverage Initiated at HC WainwrightHC Wainwright assumed coverage on shares of Avidity Biosciences in a research note on Friday. They set a "buy" rating and a $72.00 target price on the stock.December 20, 2024 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) CFO Michael F. Maclean Sells 11,151 SharesAvidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) CFO Michael F. Maclean sold 11,151 shares of the firm's stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $32.66, for a total transaction of $364,191.66. Following the sale, the chief financial officer now owns 82,942 shares of the company's stock, valued at $2,708,885.72. This trade represents a 11.85 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.December 19, 2024 | marketbeat.comInsider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells 12,742 Shares of StockAvidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) insider W. Michael Flanagan sold 12,742 shares of the business's stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $32.66, for a total transaction of $416,153.72. Following the completion of the transaction, the insider now directly owns 72,647 shares of the company's stock, valued at approximately $2,372,651.02. This represents a 14.92 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.December 19, 2024 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) CEO Sells $1,040,384.30 in StockAvidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) CEO Sarah Boyce sold 31,855 shares of the stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $32.66, for a total transaction of $1,040,384.30. Following the completion of the sale, the chief executive officer now owns 265,308 shares of the company's stock, valued at approximately $8,664,959.28. The trade was a 10.72 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.December 19, 2024 | marketbeat.comInsider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells 25,000 Shares of StockAvidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) insider Teresa Mccarthy sold 25,000 shares of the company's stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $33.26, for a total transaction of $831,500.00. Following the completion of the sale, the insider now directly owns 94,018 shares of the company's stock, valued at $3,127,038.68. The trade was a 21.01 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.December 18, 2024 | marketbeat.com Get Avidity Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter. Email Address RNA Media Mentions By Week RNA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RNA News Sentiment▼0.850.60▲Average Medical News Sentiment RNA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RNA Articles This Week▼36▲RNA Articles Average Week Get Avidity Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Genmab A/S News Today Intra-Cellular Therapies News Today Viatris News Today Moderna News Today Dr. Reddy's Laboratories News Today Vaxcyte News Today Sarepta Therapeutics News Today Qiagen News Today Ascendis Pharma A/S News Today Roivant Sciences News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RNA) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avidity Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RNA Stock Alerts